AnPac Bio Shares Jump on Cancer Treatment Technology Related Joint Venture

AnPac Bio-Medical Science Co Ltd ANPC will establish a joint venture with its founder and chairman, Dr. Chris Chang Yu, and certain other individuals to develop a new cancer treatment technology and associated products.
The company will contribute two filed patent applications in the space of cancer treatment to the Joint Venture.
Shareholding percentages of AnPac Bio and other shareholders in the Joint Venture will be determined based on the value of the patent applications and other commercial factors.
The technology will utilize findings from early-stage cancer detection work involving a database of over 222,200 samples.
The treatment modules will be fabricated by integrated circuit technology in conjunction with certain reagents to target biophysical properties exhibiting abnormal ranges within pre-cancer and cancer populations.
The technology aims to prevent disease progression for both pre-cancer and cancer patients.
Laboratory tests on the technology are expected to begin in the third quarter of 2021.
Additionally, a class III medical device registration application to the Chinese National Medical Products Administration is planned for Q3 of 2022.
Price Action: ANPC shares are +26.3% at $5.91 during the premarket session on the last check Tuesday.